Lymphoma Clinical Trials in Miami, Florida
54 recruitingMiami, Florida
Showing 1–20 of 54 trials
Recruiting
Phase 2
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Nodular Lymphocyte Predominant B-Cell LymphomaRecurrent Nodular Lymphocyte Predominant B-Cell LymphomaRefractory Nodular Lymphocyte Predominant B-Cell Lymphoma
National Cancer Institute (NCI)70 enrolled35 locationsNCT05886036
Recruiting
Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
National Cancer Institute (NCI)92 enrolled125 locationsNCT04840602
Recruiting
Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
National Cancer Institute (NCI)1,875 enrolled399 locationsNCT05675410
Recruiting
Phase 3
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Classic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features
National Cancer Institute (NCI)600 enrolled260 locationsNCT06337318
Recruiting
Phase 1
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
National Cancer Institute (NCI)47 enrolled54 locationsNCT04609046
Recruiting
Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
American Society of Clinical Oncology4,200 enrolled166 locationsNCT02693535
Recruiting
Phase 2
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
LymphomaMyelofibrosisAML (Acute Myelogenous Leukemia)+8 more
Center for International Blood and Marrow Transplant Research358 enrolled13 locationsNCT06859424
Recruiting
Phase 2
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Large B-cell Lymphoma
Allogene Therapeutics250 enrolled61 locationsNCT06500273
Recruiting
Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
B-cell Non Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRelapsed B-Cell Non Hodgkin Lymphoma
ADC Therapeutics S.A.200 enrolled42 locationsNCT04970901
Recruiting
Phase 2
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
City of Hope Medical Center33 enrolled7 locationsNCT07218510
Recruiting
Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Mixed Phenotype Acute LeukemiaLymphoblastic LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1+3 more
Children's Oncology Group440 enrolled229 locationsNCT05602194
Recruiting
Phase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Mixed Phenotype Acute LeukemiaB Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma+2 more
Children's Oncology Group5,951 enrolled230 locationsNCT03959085
Recruiting
Phase 2
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
LymphomaLymphoma, Large B-Cell, Diffuse
Jennifer Crombie, MD41 enrolled3 locationsNCT05800366
Recruiting
Phase 2
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Refractory CancerPrimary Central Nervous System LymphomaRelapsed Cancer+1 more
Baptist Health South Florida15 enrolled1 locationNCT05681195
Recruiting
Phase 4
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
Eli Lilly and Company279 enrolled36 locationsNCT06876662
Recruiting
Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Refractory Follicular LymphomaFollicular LymphomaRelapsed/Refractory Follicular Lymphoma
Epizyme, Inc.612 enrolled229 locationsNCT04224493
Recruiting
Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Loxo Oncology, Inc.249 enrolled133 locationsNCT06588478
Recruiting
Phase 4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
Eli Lilly and Company787 enrolled38 locationsNCT06876649
Recruiting
Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Lymphoma
Memorial Sloan Kettering Cancer Center83 enrolled10 locationsNCT02974647